Skip to main content

Table 1 Baseline characteristics of patients

From: Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?

 

Metformin (n = 7)

Controls (n = 7)

p value

Male Gender

3 (43)

3 (43)

1

Age (years)

53.3 ± 7.8

52.9 ± 7.4

0.918

Weight (kg)

99.4 ± 25.6

79.9 ± 11.6

0.091

BMI (kg/m2)

34.1 ± 8.8

28.0 ± 3.5

0.118

Blood Pressure (mm Hg)

 Systolic

131.4 ± 9.0

140 ± 15.3

0.225

 Diastolic

85.0 ± 5.8

85.0 ± 7.6

1.000

 Serum creatinine (mg/dl)

1.51 ± 0.36

1.54 ± 0.40

0.875

 eGFR (mL/min per 1·73 m2)a

48.1 ± 11.1

48.0 ± 15.5

0.994

 Haemoglobin (g/dl)

14.5 ± 2.3

13.4 ± 1.3

0.298

 Urine proteins (g/24 h)

0 [0; 3990]

131 [0; 350]

0.143

 Fasting serum glucose (mmol/L)

118.7 ± 17.6

91.3 ± 9.7

0.012

 Blood pressure lowering drugs (n)

1.71 ± 0.8

1.71 ± 1.0

1

 ACE- ARBs use

6 (86)

6 (86)

1

  1. Data are expressed as mean ± standard deviation, Median [range] or n (%)
  2. Abbreviations: GFR glomerular filtration rate, ACE-I Corverting enzyme inibitors, ARBs Angiotensin receptors blockers
  3. aMeasured by Estimated by the four-variable equation from Modification of Diet in Renal Disease study